Foley attorneys filed an amicus brief in the United States District Court for the Southern District of New York related to ACLU v. Myriad regarding subject matter patentability of gene patents specifically on isolated DNA. The authors conclude that the U.S. Congress, U.S. courts and the USPTO, as well as the scientific community and biotechnology industry have long relied upon an understanding that claims directed to “isolated DNA” recite patentable subject matter under 35 U.S.C. §101 and the Constitution. The authors maintain that to hold otherwise would have a dramatic negative effect on biotech research as we know it, and will influence the entire business of biotechnology in ways unforeseen or addressed by the plaintiffs in ACLU v. Myriad”
People
Related News
14 November 2024
Press Releases
Laura Ganoza Elected to International Trademark Association Board of Directors
Foley & Lardner LLP partner Laura Ganoza has been elected to the International Trademark Association’s (INTA) board of directors.
11 November 2024
Press Releases
Foley Adds Partner Jose Sanchez, Strengthening Securities Enforcement and Litigation Capabilities and Expanding California Presence
Foley & Lardner LLP announced today that Jose Sanchez has joined the firm’s Los Angeles office as a partner in its Securities Enforcement & Litigation Practice Group, adding to Foley’s deep bench of seasoned regulatory, investigations, and trial attorneys.
24 October 2024
Press Releases
Foley Publishes a ‘How-To’ Manufacturing Guide on Today’s Pressing Legal Challenges and Those that Lie Ahead
Foley & Lardner LLP today released its 2024 End-to-End Manufacturing Manual, a compilation of essays focused on helping companies navigate the ever-changing future of manufacturing.